Glycerin

Glycerin

SCHEMBL2967167

O=C(O)CCC(=O)OP(=O)(O)O.OCC(O)CO

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.34
KDM6B O15054 1/20 0.34
KDM5C P41229 1/20 0.34
PHF8 Q9UPP1 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34
FOLH1 Q04609 5/20 0.33
LMNA P02545 3/20 0.33
PGK1 P00558 1/20 0.33
PGK2 P07205 1/20 0.33
ALKBH5 Q6P6C2 1/20 0.33
SUCNR1 Q9BXA5 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PEPD P12955 1/20 0.32
GRM3 Q14832 2/20 0.32
PGD P52209 1/20 0.32
NAALAD2 Q9Y3Q0 1/20 0.32
CA4 P22748 1/20 0.31
KDM4E B2RXH2 1/20 0.31
DUSP3 P51452 1/20 0.31
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8561065 0.86 LMNA (0.45) EGLN1KDM6BKDM5CPHF8KDM2A
SCHEMBL28316038 0.84 LMNA (0.43) EGLN1KDM6BKDM5CPHF8KDM2A
Succinic Acid SCHEMBL2967165 0.82 LMNA (0.45) EGLN1KDM2AFOLH1LMNAALKBH5
SCHEMBL4610266 0.81 THRB (0.36) LMNAPGK1PGK2ALDH1A1PEPD
SCHEMBL29165564 0.80 LMNA (0.39) EGLN1KDM6BKDM5CPHF8KDM2A
SCHEMBL285627 0.77 CA4 (0.48) LMNAPGK1PGK2PEPDPGD
Succinic Acid SCHEMBL29758477 0.77 LMNA (0.56) EGLN1KDM6BKDM5CPHF8KDM2A
Succinic Acid SCHEMBL6854426 0.77 LMNA (0.56) EGLN1KDM6BKDM5CPHF8KDM2A
Succinic Acid SCHEMBL321511 0.77 LMNA (0.56) EGLN1KDM6BKDM5CPHF8KDM2A
Succinic Acid SCHEMBL19478236 0.77 LMNA (0.56) EGLN1KDM6BKDM5CPHF8KDM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772270-B2 Imino acid derivatives as inhibitors of matrix metalloproteinases SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-08-10 US disclosed
US-20060252752-A1 Octahydrocyclopenta[b]pyrrole-sulfonamide-2-carboxylic acid derivatives; reduced side effects SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-11-09 US disclosed
US-20050004166-A1 Imino acid derivatives as inhibitors of matrix metalloproteinases AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004166-A1 Imino acid derivatives as inhibitors of matrix metalloproteinases MMP9, MMP1, MMP25 EGLN1 697/4885KDM6B 2332/4885KDM5C 1466/4885
US-20060252752-A1 Octahydrocyclopenta[b]pyrrole-sulfonamide-2-carboxylic acid derivatives; reduced side effects SULT2A1, ADCYAP1R1, SULT1A1 EGLN1 2023/4885KDM6B 3164/4885KDM5C 3553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.